Gilead Sciences, Inc. $GILD Stock: Meeder Advisory Services Inc. Raises Stake

Meeder Advisory Services Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 38,242 shares of the biopharmaceutical company’s stock after acquiring an additional 3,277 shares during the quarter. Meeder Advisory Services Inc.’s holdings in Gilead Sciences were worth $5,700,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Benjamin Edwards Inc. raised its position in shares of Gilead Sciences by 2.7% in the third quarter. Benjamin Edwards Inc. now owns 128,930 shares of the biopharmaceutical company’s stock valued at $19,219,000 after purchasing an additional 3,405 shares during the period. CacheTech Inc. lifted its stake in shares of Gilead Sciences by 24.7% during the 3rd quarter. CacheTech Inc. now owns 15,228 shares of the biopharmaceutical company’s stock worth $2,270,000 after buying an additional 3,017 shares during the last quarter. DiPaolo Financial Group Inc. acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $42,000. First Trust Advisors LP lifted its stake in shares of Gilead Sciences by 2.5% during the 3rd quarter. First Trust Advisors LP now owns 3,065,019 shares of the biopharmaceutical company’s stock worth $456,841,000 after buying an additional 73,386 shares during the last quarter. Finally, BNP Paribas boosted its holdings in shares of Gilead Sciences by 33.5% during the 3rd quarter. BNP Paribas now owns 158,394 shares of the biopharmaceutical company’s stock worth $23,682,000 after buying an additional 39,723 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Keeley Cain Wettan sold 3,399 shares of Gilead Sciences stock in a transaction on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares of the company’s stock, valued at $879,629.60. This represents a 38.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 237,709 shares of company stock worth $39,799,137 in the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $166.33 on Friday. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The company has a 50-day simple moving average of $157.26 and a two-hundred day simple moving average of $142.46. The stock has a market capitalization of $206.30 billion, a price-to-earnings ratio of -52.64 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. During the same quarter in the prior year, the business posted $2.47 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GILD. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a research report on Friday, October 30th. Finally, UBS Group increased their target price on Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.63.

Read Our Latest Research Report on Gilead Sciences

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Articles

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.